Fresenius Kabi Oncology
Fresenius Kabi Oncology
HealthcareTapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Weaknesses
5- Stock is trading at 5.15 times its book value
- The company has delivered a poor sales growth of 10.1% over past five years.
- Tax rate seems low
- Company has a low return on equity of 6.57% over last 3 years.
- Company might be capitalizing the interest cost
Growth Rate
Quarterly Results
| Particulars | Mar 2013 | Jun 2013 | Sep 2013 | Dec 2013 |
|---|---|---|---|---|
| Sales | 93 | 127 | 96 | 85 |
| Expenses | 82 | 118 | 125 | 121 |
| Operating Profit | 11 | 8 | -29 | -37 |
| OPM % | 12% | 7% | -30% | -43% |
| Other Income | -6 | 1 | 0 | -6 |
| Interest | -2 | -5 | 7 | 10 |
| Depreciation | 7 | 7 | 8 | 8 |
| PBT | 1 | 7 | -44 | -61 |
| Tax % | 962% | 32% | 2% | 4% |
| Net Profit | -8 | 5 | -45 | -64 |
| EPS in Rs | -0.49 | 0.3 | -2.83 | -4.02 |
Profit & Loss
| Particulars | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 241 | 257 | 411 | 413 | 527 | 596 | 408 | 464 | 542 | 624 | 703 | 660 |
| Expenses | 215 | 335 | 325 | 341 | 505 | 453 | 480 | 552 | 546 | 549 | 571 | 569 |
| Operating Profit | 26 | -78 | 87 | 71 | 22 | 143 | -72 | -88 | -5 | 75 | 132 | 90 |
| OPM % | 11% | -30% | 21% | 17% | 4.2% | 24% | -18% | -19% | -0.8% | 12% | 19% | 14% |
| Other Income | 180 | 37 | 31 | 34 | 91 | -5 | -8 | -34 | -13 | 13 | -13 | -60 |
| Interest | 8 | 22 | 19 | 18 | 18 | -3 | 13 | -13 | 29 | 37 | 46 | 37 |
| Depreciation | 5 | 12 | 13 | 17 | 24 | 26 | 31 | 44 | 52 | 49 | 55 | 55 |
| PBT | 192 | -75 | 86 | 70 | 72 | 115 | -123 | -154 | -99 | 2 | 18 | -61 |
| Tax % | 22% | 4% | 7% | 30% | 29% | 30% | -10% | 2% | -17% | 213% | -6% | -12% |
| Net Profit | 149 | -78 | 80 | 49 | 51 | 81 | -111 | -157 | -83 | -2 | 20 | -54 |
| EPS in Rs | 9.53 | -4.91 | 5.07 | 3.11 | 3.22 | 5.09 | -7.04 | -9.93 | -5.22 | -0.15 | 1.24 | -3.41 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 17 | 17 | 17 | 17 | 17 |
| Reserves | 483 | 396 | 476 | 526 | 577 | 657 | 546 | 505 | 424 | 421 | 441 | 390 |
| Borrowings | 195 | 242 | 269 | 333 | 147 | 140 | 311 | 349 | 421 | 521 | 474 | 463 |
| Other Liabilities | 108 | 120 | 150 | 185 | 181 | 226 | 226 | 245 | 317 | 260 | 298 | 360 |
| Total Liabilities | 802 | 774 | 912 | 1,059 | 921 | 1,039 | 1,098 | 1,116 | 1,179 | 1,219 | 1,231 | 1,229 |
| Fixed Assets | 74 | 196 | 195 | 258 | 305 | 352 | 463 | 483 | 522 | 494 | 469 | 456 |
| CWIP | 123 | 3 | 58 | 96 | 140 | 163 | 79 | 55 | 30 | 45 | 38 | 37 |
| Investments | 183 | 129 | 129 | 126 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 421 | 447 | 529 | 579 | 476 | 524 | 556 | 578 | 626 | 680 | 724 | 736 |
| Total Assets | 802 | 774 | 912 | 1,059 | 921 | 1,039 | 1,098 | 1,116 | 1,179 | 1,219 | 1,231 | 1,229 |
Cash Flow
| Particulars | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | -65 | -55 | 56 | 50 | 174 | 128 | -53 | -121 | 8 | -39 | 112 | 98 |
| Investing | 19 | 30 | -63 | -116 | 17 | -121 | -86 | -44 | -40 | -29 | -30 | -52 |
| Financing | 49 | 28 | 32 | 49 | -196 | -20 | 140 | 164 | -48 | 147 | -29 | -10 |
| Net Cash Flow | 2 | 2 | 26 | -16 | -5 | -13 | 1 | -1 | -79 | 79 | 53 | 36 |
| Free Cash Flow | -106 | -52 | -7 | -71 | 64 | 7 | -130 | -158 | -29 | -79 | 75 | 44 |
| CFO/OP | -238 | 69 | 78 | 92 | 856 | 109 | 57 | 137 | -180 | -52 | 89 | 113 |
Ratios
| Particulars | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 142 | 145 | 134 | 156 | 140 | 113 | 100 | 93 | 90 | 83 | 84 | 83 |
| Inventory Days | 466 | 679 | 584 | 559 | 317 | 543 | 662 | 452 | 581 | 579 | 510 | 523 |
| Days Payable | 264 | 235 | 221 | 219 | 159 | 202 | 380 | 261 | 298 | 233 | 219 | 301 |
| Cash Conversion Cycle | 344 | 589 | 497 | 496 | 298 | 454 | 382 | 283 | 372 | 430 | 375 | 305 |
| Working Capital Days | 453 | 462 | 307 | 337 | 206 | 193 | 292 | 261 | 221 | 258 | 233 | 213 |
| ROCE % | 34% | -8% | 13% | 10% | 6% | 15% | -11% | -14% | -5% | 4% | 11% | 9% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Fresenius Kabi Oncology insights
60 extracted metrics + investor summaries across FY08–FY19.
Documents
Frequently Asked Questions about Fresenius Kabi Oncology
What does Fresenius Kabi Oncology Ltd do?
Which sector does Fresenius Kabi Oncology Ltd belong to?
Company Information
Fresenius Kabi Oncology Limited engages in the development, manufacture, and marketing of chemotherapeutic drugs for the treatment of cancer.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/FKONCO.md for Fresenius Kabi Oncology Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.